Ischemic stroke remains a leading cause of morbidity and death for which few therapeutic options are available. The development of neuroprotective agents, a once promising field of investigation, has failed to translate from bench to bedside successfully. This work reviews the ischemic cascade, agents targeting steps within the cascade, and potential reasons for lack of translation. Additional therapeutic targets are highlighted and areas requiring further investigation are discussed. It is clear that alternative targets need to be pursued, such as the role glia play in neurological injury and recovery, particularly the interactions between neurons, astrocytes, microglia, and the vasculature. Similarly, the biphasic nature of many signaling molecules such as matrix metalloproteinases and high-mobility group box 1 protein must be further investigated to elucidate periods of detrimental versus beneficial activity.
Please include this information when citing this paper: published online January 18, 2012; DOI: 10.3171/2012.11.JNS12408.
Albers GW, , Atkinson RP, , Kelley RE, & Rosenbaum DM: Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26:254–258, 1995
Albers GW, , Goldstein LB, , Hall D, & Lesko LM: Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 286:2673–2682, 2001
Astrup J, , Symon L, , Branston NM, & Lassen NA: Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 8:51–57, 1977
Badan I, , Buchhold B, , Hamm A, , Gratz M, , Walker LC, & Platt D, et al.: Accelerated glial reactivity to stroke in aged rats correlates with reduced functional recovery. J Cereb Blood Flow Metab 23:845–854, 2003
Barber PA, , Zhang J, , Demchuk AM, , Hill MD, & Buchan AM: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 56:1015–1020, 2001
Becker KJ: Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Curr Med Res Opin 18:Suppl 2 s18–s22, 2002
Block ML, , Zecca L, & Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69, 2007
Bordi F, , Pietra C, , Ziviani L, & Reggiani A: The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat. Exp Neurol 145:425–433, 1997
Bowes MP, , Rothlein R, , Fagan SC, & Zivin JA: Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology 45:815–819, 1995
Braeuninger S, & Kleinschnitz C: Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems. Exp Transl Stroke Med 1:8, 2009
Bredesen DE: Apoptosis: overview and signal transduction pathways. J Neurotrauma 17:801–810, 2000
Broughton BR, , Reutens DC, & Sobey CG: Apoptotic mechanisms after cerebral ischemia. Stroke 40:e331–e339, 2009
Burns TC, & Steinberg GK: Stem cells and stroke: opportunities, challenges and strategies. Expert Opin Biol Ther 11:447–461, 2011
Candelario-Jalil E: Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. Curr Opin Investig Drugs 10:644–654, 2009
Carmignoto G, & Gómez-Gonzalo M: The contribution of astrocyte signalling to neurovascular coupling. Brain Res Brain Res Rev 63:138–148, 2010
Cheney JA, , Weisser JD, , Bareyre FM, , Laurer HL, , Saatman KE, & Raghupathi R, et al.: The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J Cereb Blood Flow Metab 21:396–403, 2001
Clark WM, , Raps EC, , Tong DC, & Kelly RE: Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. Stroke 31:1234–1239, 2000
Cotrina ML, & Nedergaard M: Astrocytes in the aging brain. J Neurosci Res 67:1–10, 2002
Davis SM, , Lees KR, , Albers GW, , Diener HC, , Markabi S, & Karlsson G, et al.: Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31:347–354, 2000
De Ryck M, , Keersmaekers R, , Duytschaever H, , Claes C, , Clincke G, & Janssen M, et al.: Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther 279:748–758, 1996
del Zoppo GJ: The neurovascular unit in the setting of stroke. J Intern Med 267:156–171, 2010
Diener HC, , Cortens M, , Ford G, , Grotta J, , Hacke W, & Kaste M, et al.: Lubeluzole in acute ischemic stroke treatment: a double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke 31:2543–2551, 2000
Diener HC, , Lees KR, , Lyden P, , Grotta J, , Davalos A, & Davis SM, et al.: NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39:1751–1758, 2008
Dinapoli VA, , Benkovic SA, , Li X, , Kelly KA, , Miller DB, & Rosen CL, et al.: Age exaggerates proinflammatory cytokine signaling and truncates signal transducers and activators of transcription 3 signaling following ischemic stroke in the rat. Neuroscience 170:633–644, 2010
Du C, , Hu R, , Hsu CY, & Choi DW: Dextrorphan reduces infarct volume, vascular injury, and brain edema after ischemic brain injury. J Neurotrauma 13:215–222, 1996
Durukan A, , Strbian D, & Tatlisumak T: Rodent models of ischemic stroke: a useful tool for stroke drug development. Curr Pharm Des 14:359–370, 2008
Enlimomab Acute Stroke Trial Investigators: Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 57:1428–1434, 2001
Faden AI, , Shirane R, , Chang LH, , James TL, , Lemke M, & Weinstein PR: Opiate-receptor antagonist improves metabolic recovery and limits neurochemical alterations associated with reperfusion after global brain ischemia in rats. J Pharmacol Exp Ther 255:451–458, 1990
Fagan SC, , Cronic LE, & Hess DC: Minocycline development for acute ischemic stroke. Transl Stroke Res 2:202–208, 2011
Fisher M, , Feuerstein G, , Howells DW, , Hurn PD, , Kent TA, & Savitz SI, et al.: Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 40:2244–2250, 2009
Fogelholm R, , Erilä T, , Palomäki H, , Murros K, & Kaste M: Effect of nimodipine on final infarct volume after acute ischemic stroke. Cerebrovasc Dis 10:189–193, 2000
Graham SH, , Chen J, & Simon RP: A dose-response study of dextrorphan in permanent focal ischemia. Neurosci Lett 160:21–23, 1993
Guevara R, , Gianotti M, , Oliver J, & Roca P: Age and sex-related changes in rat brain mitochondrial oxidative status. Exp Gerontol 46:923–928, 2011
Hayakawa K, , Mishima K, , Nozako M, , Hazekawa M, , Mishima S, & Fujioka M, et al.: Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 39:951–958, 2008
Hayakawa K, , Nakano T, , Irie K, , Higuchi S, , Fujioka M, & Orito K, et al.: Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 30:871–882, 2010
Hayakawa K, , Qiu J, & Lo EH: Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci 1207:50–57, 2010
Heidenreich PA, , Trogdon JG, , Khavjou OA, , Butler J, , Dracup K, & Ezekowitz MD, et al.: Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123:933–944, 2011
Hellström HO, , Wanhainen A, , Valtysson J, , Persson L, & Hillered L: Effect of tirilazad mesylate given after permanent middle cerebral artery occlusion in rat. Acta Neurochir (Wien) 129:188–192, 1994
Horn J, , de Haan RJ, , Vermeulen M, & Limburg M: Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial. Stroke 32:461–465, 2001
Hossmann KA: Pathophysiological basis of translational stroke research. Folia Neuropathol 47:213–227, 2009
Hossmann KA: Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol 26:1057–1083, 2006
Huang J, , Upadhyay UM, & Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol 66:232–245, 2006
Jensen BS: BMS-204352: a potassium channel opener developed for the treatment of stroke. CNS Drug Rev 8:353–360, 2002
Jin R, , Yang G, & Li G: Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 87:779–789, 2010
Jin R, , Yang G, & Li G: Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 38:376–385, 2010
Johnson EM Jr, , Greenlund LJ, , Akins PT, & Hsu CY: Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury. J Neurotrauma 12:843–852, 1995
Joly LM, , Mucignat V, , Mariani J, , Plotkine M, & Charriaut-Marlangue C: Caspase inhibition after neonatal ischemia in the rat brain. J Cereb Blood Flow Metab 24:124–131, 2004
Jordán J, , Segura T, , Brea D, , Galindo MF, & Castillo J: Inflammation as therapeutic objective in stroke. Curr Pharm Des 14:3549–3564, 2008
Kelly KA, , Li X, , Tan Z, , VanGilder RL, , Rosen CL, & Huber JD: NOX2 inhibition with apocynin worsens stroke outcome in aged rats. Brain Res 1292:165–172, 2009
Kristián T, & Siesjö BK: Calcium in ischemic cell death. Stroke 29:705–718, 1998
Kunz A, , Dirnagl U, & Mergenthaler P: Acute pathophysiological processes after ischaemic and traumatic brain injury. Best Pract Res Clin Anaesthesiol 24:495–509, 2010
Labiche LA, & Grotta JC: Clinical trials for cytoprotection in stroke. NeuroRx 1:46–70, 2004
Lacy CR, , Suh DC, , Bueno M, & Kostis JB: Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). Stroke 32:63–69, 2001
Lampl Y, , Boaz M, , Gilad R, , Lorberboym M, , Dabby R, & Rapoport A, et al.: Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 69:1404–1410, 2007
Lees KR, , Asplund K, , Carolei A, , Davis SM, , Diener HC, & Kaste M, et al.: Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet 355:1949–1954, 2000
Liu F, , Yuan R, , Benashski SE, & McCullough LD: Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab 29:792–802, 2009
Liu S, , Zhen G, , Meloni BP, , Campbell K, & Winn HR: Rodent stroke model guidelines for preclinical stroke trials (1st edition). J Exp Stroke Transl Med 2:2–27, 2009
Lo EH: Experimental models, neurovascular mechanisms and translational issues in stroke research. Br J Pharmacol 153:Suppl 1 S396–S405, 2008
Lo EH: A new penumbra: transitioning from injury into repair after stroke. Nat Med 14:497–500, 2008
Lo EH, , Dalkara T, & Moskowitz MA: Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 4:399–415, 2003
Lyden P, , Shuaib A, , Ng K, , Levin K, , Atkinson RP, & Rajput A, et al.: Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke 33:122–128, 2002
Macleod MR, , O'Collins T, , Horky LL, , Howells DW, & Donnan GA: Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25:713–721, 2005
MacManus JP, & Buchan AM: Apoptosis after experimental stroke: fact or fashion?. J Neurotrauma 17:899–914, 2000
Madden KP, , Clark WM, & Zivin JA: Delayed therapy of experimental ischemia with competitive N-methyl-D-aspartate antagonists in rabbits. Stroke 24:1068–1071, 1993
Maeda M, , Furuichi Y, , Noto T, , Matsuoka N, , Mutoh S, & Yoneda Y: Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model. Brain Res 1254:99–108, 2009
Marshall JW, , Cross AJ, & Ridley RM: Functional benefit from clomethiazole treatment after focal cerebral ischemia in a nonhuman primate species. Exp Neurol 156:121–129, 1999
Mauler F, & Horváth E: Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury. J Cereb Blood Flow Metab 25:451–459, 2005
McCullough LD, , Alkayed NJ, , Traystman RJ, , Williams MJ, & Hurn PD: Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke 32:796–802, 2001
Meadows ME, , Fisher M, & Minematsu K: Delayed treatment with a noncompetitive nmda antagonist, CNS-1102, reduces infarct size in rats. Cerebrovasc Dis 4:26–31, 1994
Meden P, , Overgaard K, , Pedersen H, & Boysen G: Effect of early treatment with tirilazad (u74006f) combined with delayed thrombolytic therapy in rat embolic stroke. Cerebrovasc Dis 6:141–148, 1996
Mizoguchi H, , Leitermann RJ, , Narita M, , Nagase H, , Suzuki T, & Tseng LF: Region-dependent G-protein activation by kappa-opioid receptor agonists in the mouse brain. Neurosci Lett 356:145–147, 2004
Muir KW: Magnesium in stroke treatment. Postgrad Med J 78:641–645, 2002
Nakamura H, , Strong AJ, , Dohmen C, , Sakowitz OW, , Vollmar S, & Sué M, et al.: Spreading depolarizations cycle around and enlarge focal ischaemic brain lesions. Brain 133:1994–2006, 2010
Nakanishi H, & Wu Z: Microglia-aging: roles of microglial lysosome- and mitochondria-derived reactive oxygen species in brain aging. Behav Brain Res 201:1–7, 2009
Nakase T, , Maeda T, , Yoshida Y, & Nagata K: Ischemia alters the expression of connexins in the aged human brain. J Biomed Biotechnol 2009:147946, 2009
North American Glycine Antagonist in Neuroprotection (GAIN) Investigators: Phase II studies of the glycine antagonist GV150526 in acute stroke: the North American experience. Stroke 31:358–365, 2000
Nuttall ME, , Lee D, , McLaughlin B, & Erhardt JA: Selective inhibitors of apoptotic caspases: implications for novel therapeutic strategies. Drug Discov Today 6:85–91, 2001
O'Collins VE, , Macleod MR, , Donnan GA, , Horky LL, , van der Worp BH, & Howells DW: 1,026 experimental treatments in acute stroke. Ann Neurol 59:467–477, 2006
Orset C, , Haelewyn B, , Vivien K, , Vivien D, & Young AR, Rodent models of thromboembolic stroke. Dirnagl U: Rodent Models of Stroke New York, Springer, 2010. 47:55–70
Pettigrew LC, , Kasner SE, , Albers GW, , Gorman M, , Grotta JC, & Sherman DG, et al.: Safety and tolerability of arundic acid in acute ischemic stroke. J Neurol Sci 251:50–56, 2006
Pilegaard K, & Ladefoged O: Total number of astrocytes in the molecular layer of the dentate gyrus of rats at different ages. Anal Quant Cytol Histol 18:279–285, 1996
Popa-Wagner A, , Carmichael ST, , Kokaia Z, , Kessler C, & Walker LC: The response of the aged brain to stroke: too much, too soon?. Curr Neurovasc Res 4:216–227, 2007
Robertson GS, , Crocker SJ, , Nicholson DW, & Schulz JB: Neuroprotection by the inhibition of apoptosis. Brain Pathol 10:283–292, 2000
Roda JM, , Carceller F, , Díez-Tejedor E, & Avendaño C: Reduction of infarct size by intra-arterial nimodipine administered at reperfusion in a rat model of partially reversible brain focal ischemia. Stroke 26:1888–1892, 1995
Rosen CL, , Dinapoli VA, , Nagamine T, & Crocco T: Influence of age on stroke outcome following transient focal ischemia. J Neurosurg 103:687–694, 2005
Rossi DJ, , Brady JD, & Mohr C: Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci 10:1377–1386, 2007
Saver JL, , Kidwell C, , Eckstein M, & Starkman S: Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FASTMAG) pilot trial. Stroke 35:e106–e108, 2004
Savitz SI: A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 205:20–25, 2007
Semkova I, , Wolz P, & Krieglstein J: Neuroprotective effect of 5-HT1A receptor agonist, Bay X 3702, demonstrated in vitro and in vivo. Eur J Pharmacol 359:251–260, 1998
Shuaib A, & Hussain MS: The past and future of neuroprotection in cerebral ischaemic stroke. Eur Neurol 59:4–14, 2008
Shuaib A, , Ijaz S, & Kanthan R: Clomethiazole protects the brain in transient forebrain ischemia when used up to 4 h after the insult. Neurosci Lett 197:109–112, 1995
Shuaib A, , Lees KR, , Lyden P, , Grotta J, , Davalos A, & Davis SM, et al.: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 357:562–571, 2007
Siesjö BK: Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. J Neurosurg 77:169–184, 1992
Smith WS: Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol 15:S3–S12, 2004
Sorbera LA, , Castaner J, & Castaner RM: Arundic acid. Drugs Future 29:441–449, 2004
Stankowski JN, & Gupta R: Therapeutic targets for neuroprotection in acute ischemic stroke: lost in translation?. Antioxid Redox Signal 14:1841–1851, 2011
Starkov AA, , Chinopoulos C, & Fiskum G: Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 36:257–264, 2004
Stroke Therapy Academic Industry Roundtable (STAIR): Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30:2752–2758, 1999
Suzuki M, , Sasamata M, & Miyata K: Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model. Brain Res 959:169–172, 2003
Switzer JA, , Hess DC, , Ergul A, , Waller JL, , Machado LS, & Portik-Dobos V, et al.: Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 42:2633–2635, 2011
Takamatsu H, , Tsukada H, , Noda A, , Kakiuchi T, , Nishiyama S, & Nishimura S, et al.: FK506 attenuates early ischemic neuronal death in a monkey model of stroke. J Nucl Med 42:1833–1840, 2001
Takano T, , Oberheim N, , Cotrina ML, & Nedergaard M: Astrocytes and ischemic injury. Stroke 40:3 Suppl S8–S12, 2009
Tateishi N, , Mori T, , Kagamiishi Y, , Satoh S, , Katsube N, & Morikawa E, et al.: Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(-) -2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 22:723–734, 2002
Teal P, , Davis S, , Hacke W, , Kaste M, , Lyden PD, & Fierus M: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT). Stroke 40:3518–3525, 2009
Tirilazad International Steering Committee: Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke 31:2257–2265, 2000. (Erratum in Stroke 32:279, 2001)
Toung TJ, , Traystman RJ, & Hurn PD: Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke 29:1666–1670, 1998
Tripathy D, , Yin X, , Sanchez A, , Luo J, , Martinez J, & Grammas P: Cerebrovascular expression of proteins related to inflammation, oxidative stress and neurotoxicity is altered with aging. J Neuroinflammation 7:63, 2010
Vibulsresth S, , Dietrich WD, , Busto R, & Ginsberg MD: Failure of nimodipine to prevent ischemic neuronal damage in rats. Stroke 18:210–216, 1987
Viscoli CM, , Brass LM, , Kernan WN, , Sarrel PM, , Suissa S, & Horwitz RI: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243–1249, 2001
Wang Q, , Tang XN, & Yenari MA: The inflammatory response in stroke. J Neuroimmunol 184:53–68, 2007
Wang X, , Han W, , Du X, , Zhu C, , Carlsson Y, & Mallard C, et al.: Neuroprotective effect of Bax-inhibiting peptide on neonatal brain injury. Stroke 41:2050–2055, 2010
Weiser T: AMPA receptor antagonists for the treatment of stroke. Curr Drug Targets CNS Neurol Disord 4:153–159, 2005
Yang Y, , Li Q, , Ahmad F, & Shuaib A: Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett 285:119–122, 2000
Yenari MA, , Kunis D, , Sun GH, , Onley D, , Watson L, & Turner S, et al.: Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Exp Neurol 153:223–233, 1998
Zipfel GJ, , Babcock DJ, , Lee JM, & Choi DW: Neuronal apoptosis after CNS injury: the roles of glutamate and calcium. J Neurotrauma 17:857–869, 2000
Zonta M, , Angulo MC, , Gobbo S, , Rosengarten B, , Hossmann KA, & Pozzan T, et al.: Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat Neurosci 6:43–50, 2003
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1099 | 249 | 7 |
Full Text Views | 182 | 10 | 2 |
PDF Downloads | 111 | 18 | 4 |
EPUB Downloads | 0 | 0 | 0 |